Pharmacological targeting of IRE1α could be explored as a strategy to mitigate endothelial dysfunction and its complications in diseases characterized by systemic or localized fever, such as sepsis, Kawasaki disease, or even certain autoimmune conditions (e.g., lupus erythematosus). The gene discussed is ERN1; the disease is endothelial dysfunction.